Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Economists around the world are expecting muted U.S. economic growth in the coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...

A Mounjaro user has revealed what happened when they accidentally overdosed using the controversial 'golden dose'. ICYMI, ...

The Mounjaro 'golden dose' has been explained after doctors issued an urgent warning over the potential deadly hack.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...